1 / 3

Hepatitis C - Drug Pipeline Analysis and Market to 2016

Hepatitis C Market is Forecast to Show Significant Growth until 2016

rgunnam
Télécharger la présentation

Hepatitis C - Drug Pipeline Analysis and Market to 2016

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis C - Drug Pipeline Analysis and Market Forecasts to 2016

  2. Hepatitis C Market is Forecast to Show Significant Growth until 2016 GlobalData’s analysis suggests that the global hepatitis C market was worth $4.4 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.8% for the next seven years to reach $8.5 billion by 2016. The high projected growth rate is primarily attributable to a strong pipeline. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the hepatitis C market. GlobalData analyzed the current competitive landscape for hepatitis C drugs and found that the competition is weak. There are six commonly used approved products for the treatment of hepatitis C. The combination therapy of Peginterferon alfa 2b from Merck & Co., and Peginterferon alfa 2a from Roche are the two approved combination therapies present in the market for the treatment of hepatitis C. Generics do not hold a major share in the market. GlobalData’s analysis of the entire competitive landscape of the branded products shows weak competition between the available treatments for hepatitis C. The competition is weak due to a lack of competing products for the combination therapies. The market has a huge potential for molecules with better safety and efficacy profiles. For further details please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Hepatitis-C-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Strong Clinical Pipeline with Several First-in-Class Molecules GlobalData analyzed the hepatitis C pipeline and found it to be strong. The pipeline for hepatitis C consists of around 169 molecules currently in development. Most of these molecules are first-in-class and are promising better safety and efficacy profiles. There are approximately seven molecules in the Phase III clinical trial development stage. For example, SCH 503034(Merck), albinterferon alfa-2b (Human Genome Sciences, Inc.and novartis), RG7128 (Roche) and VX-950(Vertex and Tibotec pharmaceuticals) are among the most promising molecules in pipeline for the treatment of hepatitis C. A strong clinical pipeline coupled with high unmet needs in the hepatitis C market is expected to help sustain the market’s high growth rate during the forecast period.

  3. The Hepatitis C Market Has High Unmet Need The global hepatitis C market is attractive, with high levels of unmet need. The unmet need in the market is around 70%, which is approximately $3 billion. Some of the unmet needs in this market are due to the lack of availability of effective treatment options and the moderate safety profiles of the marketed drugs. The efficacy of the marketed products in hepatitis C market is only moderate. The safety profiles of the products available to treat hepatitis C are low and some serious side effects are associated with the drugs that may even lead to death in rare cases. The adverse effects of the drugs include pregnancy, mental health problems, blood related disorders and autoimmune disorders. Patients using the standard interferon combination therapy to treat hepatitis C soon develop resistance against these drugs and must wait for novel therapies to enter the market. Apart from various drugs that are available for the treatment of hepatitis C, certain biosimilars like interferon alfa-2a and interferon beta-1a can also drive the hepatitis C market in future. There is huge untapped potential in the current hepatitis C market which could be captured by novel molecules, targeted to fulfill the current void left by the existing treatment options. Thus the hepatitis C market has high potential for further research and development (R&D) activities. For further details please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Hepatitis-C-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Visit our report store: http://www.globaldata.com/reportstore Contact Information: Rajesh Gunnam rgunnam@globaldata.com +914066166782

More Related